Combined entity bolsters expertise to help
Pharma optimize commercial performance in the face of mounting
regulatory and commercial pressures on net revenue
PHILADELPHIA, July 9, 2024
/PRNewswire/ -- IntegriChain, delivering pharma's comprehensive
technology, data, consulting, and outsourcing platform for
data-driven commercialization, today announced the acquisition of
Federal Compliance Solutions (FCS), a leading Pharma advisory
and managed services firm. This transaction creates the industry's
deepest team of experts in government pricing and payer/provider
contracting, areas that have simultaneously become more outsourced
in Pharma and the focus of significant regulatory and commercial
changes. The combination builds on the technology, people, and
process capabilities that the two firms have developed to help the
industry develop more profitable drug commercialization strategies,
drive more profitable daily business decisioning, and improve net
revenue controls around growing price concessions to payers,
providers, and channels.
"As drug pricing and reimbursement have grown increasingly
complicated, more and more Pharma manufacturers have embraced
outsourcing options where service providers perform price
calculations and adjudicate rebates and chargebacks on their
behalf," said Josh Halpern, CEO of
IntegriChain. "This is a dynamic market with rapidly changing
regulations, vertically integrating ecosystems, and increasingly
diverse drug archetypes. IntegriChain and FCS together support more
than 200 manufacturer's contracts and pricing, gross-to-net,
channel, and data operations with outsourcing solutions. We know
that the success of the outsourcing model rides on delivering
differentiated expertise to our customers, and doing so
proactively. That's hard to do without depth. We welcome FCS
to our extensive organization of more than 200 experts across our
Strategy Consulting, Advisory Services, SaaS & BPaaS, and
Product & Technology – all of whom proudly represent the
leading team focused on improving the profitability of drug
commercialization."
"Now more than ever, Pharma companies need a trusted partner –
both to guide commercialization decisioning as well as to drive
technological efficiencies," said Rick
Moore, Managing Partner of FCS. "FCS has proven its trusted
status through our focus on domain knowledge and quality.
IntegriChain has established itself as a proven data and technology
innovator, combining forces with others to create a leading net
revenue management outsourcing and consulting capability. We are
excited to join IntegriChain's family and platform and look forward
to our combined teams continuing to partner with Pharma
manufacturers of all sizes and types and driving innovation in
contracts & pricing and gross-to-net."
The companies plan to jointly advance their portfolio of
solutions and consultative services for today's top commercial
challenges, including increasingly complicated drug contracting,
340B's explosive growth, the Inflation Reduction Act's impact on
pricing and reimbursement, and rapidly evolving drug distribution
channels.
For the foreseeable, there will be no changes to IntegriChain's
nor FCS's Advisory Services delivery teams, systems, or processes.
In 2025, the combined company will work to integrate the Advisory
Services and BPaaS offerings in the ICyte Platform, driving
innovation to deliver best-in-class offerings.
Under terms of the agreement, IntegriChain acquired the equity
of Federal Compliance Solutions LLC. The entire leadership and
professional team will join IntegriChain's global workforce that
spans nearly 750 professionals. This acquisition is IntegriChain's
seventh expansion. Fairmount Partners acted as exclusive financial
advisor to FCS.
About Federal Compliance Solutions
FCS, founded in
2017 by Pharma industry experts, is a leading life sciences
consulting firm, specialized in helping pharmaceutical and biotech
companies with strategies and solutions to optimize their
government pricing, contracting, and gross-to-net revenue
management. FCS's accomplished team of more than 60 professionals
has extensive experience in a diverse range of government programs,
SPTR, contracting, GTN, and FMV matters. FCS also supports
pharmaceutical and biotechnology companies of all sizes with a wide
range of day-to-day operational processes and ongoing compliance
requirements through its managed services offerings, including
government pricing calculating and reporting, rebate and fee
services, VA support, FMV and BFSF support, and GTN forecasting and
accrual management.
About IntegriChain
IntegriChain helps pharma
manufacturers bring their science to market, ensuring patients have
affordable, timely, and sustainable access to therapy. IntegriChain
delivers Pharma's only data-driven commercialization platform —
from strategy to operational execution. The Company's unique focus
on data, technology, consulting, and outsourcing helps connect the
commercial, financial, and operational dimensions of drug access
and profitability. Through the ICyte Platform, IntegriChain enables
pharmaceutical innovators to achieve better commercial outcomes by
digitalizing daily and recurring business activities and by
integrating data and operations across contracting, pricing,
channel and distribution, and gross-to-net. IntegriChain is backed
by Nordic Capital, a leading sector-specialized private equity
investor with a broad portfolio in Healthcare and Technology, and
is headquartered in Philadelphia,
PA, with offices in Ambler,
PA, and Pune, India. For
more information, visit www.integrichain.com or follow on
LinkedIn.
Contact
Jennifer
Guinan, Sage Strategic Marketing, jennifer@sagestrat.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/integrichain-acquires-federal-compliance-solutions-creating-pharmas-deepest-contracts--pricing-and-gross-to-net-advisory-and-outsourcing-team-302191462.html
SOURCE IntegriChain